Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PTSD
Biotech
Neuphoria nixes social anxiety program after phase 3 flop
Neuphoria’s stock has plummeted 67% after the announcement, dropping from Monday’s close of $15.40 per share to $5 as of 10 a.m. ET today.
Gabrielle Masson
Oct 21, 2025 10:44am
Transcend links MDMA analog to PTSD improvements in phase 2
Mar 31, 2025 8:00am
Lykos 'regrets' not disclosing study violations with publisher
Aug 12, 2024 3:39pm
Lykos' MDMA treatment for PTSD has been quashed at the FDA
Aug 10, 2024 9:07am
Compass tracks PTSD improvements in midphase psilocybin trial
May 8, 2024 8:07am
FDA advisers to weigh first psychedelic therapy in early June
May 7, 2024 11:10am
